Dongkook Pharmaceutical Signs Platform-Based New Drug Development Research Agreement with University of Wisconsin

[Asia Economy Reporter Lee Gwanju] Dongkook Pharmaceutical announced on the 19th that it has signed a joint research agreement with the University of Wisconsin-Madison in the United States for new drug research and product development.

Under this agreement, the University of Wisconsin will conduct material optimization and academic research for the 'drug delivery system-peptide complex' (DKF-DC101), while Dongkook Pharmaceutical will carry out toxicity and efficacy evaluations and preclinical trials for drug development.

Dongkook Pharmaceutical and the University of Wisconsin aim to develop a product using a specific drug delivery technology that has superior anticancer effects and improved cost-effectiveness compared to existing third-generation immune checkpoint inhibitors or equivalent therapies.

Third-generation immune checkpoint inhibitors are drugs that prevent cancer cells from evading the body's immune system or help immune cells better recognize and attack cancer cells. Because they act through the body's immune system, they generally have fewer side effects than traditional anticancer drugs and show remarkable therapeutic effects in some patients; however, overall low response rates and the development of resistance have been noted as areas for improvement.

Kang Suyeon, head of Dongkook Pharmaceutical's DK Drug Research Institute, said, "Based on the comprehensive analysis of basic research results so far, 'DKF-DC101' is expected to be developed as a treatment with superior anticancer effects compared to third-generation immune checkpoint inhibitors," adding, "in particular, the drug delivery system used here is a platform technology that is expected to create a 'win-win' synergy with the peptide delivery platform capabilities owned by our company and the University of Wisconsin."

This content was produced with the assistance of AI translation services.